Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Nationwide Fund Advisors
Nationwide Fund Advisors grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 46.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,829 shares of the biopharmaceutical company’s stock after buying an additional 24,639 shares during the period. Nationwide Fund Advisors owned 0.07% of Regeneron Pharmaceuticals worth $38,225,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. Gabelli Funds LLC raised its holdings in shares of Regeneron Pharmaceuticals by 13.3% in the first quarter. Gabelli Funds LLC now owns 6,800 shares of the biopharmaceutical company’s stock worth $2,635,000 after buying an additional 800 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,641 shares of the biopharmaceutical company’s stock worth $2,186,000 after buying an additional 1,307 shares during the last quarter. TFS Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $480,000. Toronto Dominion Bank raised its holdings in shares of Regeneron Pharmaceuticals by 57.4% in the first quarter. Toronto Dominion Bank now owns 20,540 shares of the biopharmaceutical company’s stock worth $7,958,000 after buying an additional 7,487 shares during the last quarter. Finally, NEXT Financial Group Inc raised its holdings in shares of Regeneron Pharmaceuticals by 2.3% in the first quarter. NEXT Financial Group Inc now owns 916 shares of the biopharmaceutical company’s stock worth $356,000 after buying an additional 21 shares during the last quarter. 67.96% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/15/regeneron-pharmaceuticals-inc-regn-shares-bought-by-nationwide-fund-advisors.html.
Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.21% on Friday, reaching $435.92. 289,912 shares of the company’s stock traded hands. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55. The firm has a market capitalization of $46.22 billion, a P/E ratio of 43.73 and a beta of 1.65. The stock has a 50-day moving average of $474.95 and a 200 day moving average of $444.94.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.90 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 56,213 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $474.48, for a total value of $26,671,944.24. Following the completion of the transaction, the chairman now owns 363,638 shares of the company’s stock, valued at $172,538,958.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Sanofi acquired 166,415 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. Insiders have sold 99,543 shares of company stock valued at $47,831,369 in the last three months. Corporate insiders own 10.40% of the company’s stock.
A number of research analysts have issued reports on the stock. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Robert W. Baird cut shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $472.00 price target (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price for the company in a report on Wednesday, August 9th. Finally, Leerink Swann reissued an “outperform” rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $491.43.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.